Grateful to receive an ASCO Young Investigator Award for our work investigating mechanisms of resistance and response to momelotinib plus gilteritinib in FLT3-mutated AML. Thank you to my mentors @HusseinAbbasLab and @NicholasShortMD for their guidance and support #ASCO2026

Our new review explores how the definition of high-risk Ph ALL is shifting across tx eras. Risk is dynamic, shaped by the interplay of biology, response, and treatment context. We examine key determinants, their evolving relevance, and risk-adapted strategies in the current era.

Kudos @Daver_Leukemia and @NicholasShortMD on not just your beautiful work but your outstanding mentorship of Dr. Azevedo! Outstanding long term follow up for aza ven gilt for adults w FLT3m AML inappropriate IC. #ASH25 #ASHScavengerHunt

Check out our most recent publication in @BloodCancerJnl evaluating the prognostic impact of early NGS-based MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL. nature.com/articles/s41408-0… @NicholasShortMD @DrHKantarjian #Leusm #ALLsm

🚨 long-term outcomes in FLT3-m AML w/frontline HMA VEN FLT3 i 🔴93% CR/CRi in ND FLT3-m AML. 🔴3-yr OS: 45% (FLT3-ITD), 76% (FLT3-TKD) 🔴RASp mutations ➡️ poor survival 🔴ITD NGS MRD highly prognostic 🔴FLT3 wild-type relapses common. #Leusm #hemepath haematologica.org/article/vi…

WBC >70K (but not IKZF1plus) increases risk of relapse with blina ponatinib in Ph ALL, particularly extramedullary/CNS. Pts with high WBC should be considered for systemic MTX/Ara-C and/or CAR T-cell consolidation jhoonline.biomedcentral.com/… #leusm #ALL

Measurable residual disease is a powerful predictor of clinical outcomes in acute lymphoblastic leukemia. ow.ly/Y2iM50VonWG #MRD #ALL #lymphoidneoplasia

Expert recommendations on using MRD in #ALL now out in @BloodAdvances. ClonoSEQ (NGS MRD) is superior to other MRD methods and should guide decisions about CAR T-cells or SCT @MDAndersonNews #Leukemia doi.org/10.1182/bloodadvance… #leusm

Recommendations from a panel of US experts published in @BloodAdvances highlight the optimal use of MRD as a prognostic and therapeutic tool in adult ALL More news: loom.ly/EvtL7yw #ALLsm #leusm #MedNews #MedEd

Early attainment of undetectable MRD by MFC is independently associated w/ improved RFS in newly diagnosed #AML. Intermediate risk pts who attain undetectable MRD should still undergo consolidative allo-SCT. @MDAndersonNews #Leukemia @ASH_hematology ashpublications.org/bloodadv…

Very nice of @AjHematology to add a wonderful visual abstract to accompany our review article on MRD in AML. Link here: onlinelibrary.wiley.com/doi/… @DillonHaem

CONGRESS #ASH24 | PRESENTATION @WNMacaron, @MDAndersonNews and @bcmhouston discussed achievement of MRD negativity and positive long-term outcomes in B-ALL. In pts with PH- B-ALL , 2-yr RFS was higher in pts who were MRD neg after cycle 1, vs those who were pos after cycle 1. Poorer outcomes occurred in pts with HR B-ALL and slow MRD response. Follow our live feed for more updates: lymphoblastic-hub.com/medica… #ALL #ALLsm

CONGRESS #ASH24 | PRESENTATION Roberta Santos Azevedo, @MDAndersonNews discussed older age and TP53 mutations as predictors of myeloid neoplasm. Incidence of t-MN was highest in pts older than 60, and also higher with treatment intensity and TP53 mutation. t-MN risk was highest in pts over 60 with TP53 mutation, with a 5-yr CI of 25% Follow our live feed for more updates: lymphoblastic-hub.com/medica… #ALL #ALLsm

CONGRESS | #ASH24 | PRESENTATION @NicholasShortMD @MDAndersonNews shares long-term findings from a study of patients with ND FLT3m AML treated with HMA Ven FLT3i triplet (N = 73). ▪️Efficacy overall was comparable to that seen with doublet therapy, and at median follow-up of 26 months, median RFS=28.8 months and median OS = 38.5 months. ▪️Differences were seen between patients FT3-ITD (mOS=28.1 months) and FLT3-TKD (mOS=39.3 months). ▪️Age, NPM1, ELN 2022 risk, or allo-HSCT did not impact survival. ▪️In the 17 patients who relapsed with available sequencing information, 65% were FLT3 negative at relapse; 12 patients had clonal evolution, with new RAS pathway mutations identified in 24%. ▪️Poor responses were observed with triplet therapy post-relapse, particularly in patients with FLT3 mutation at relapse (median OS = 1.6 months). Follow our live feed for more updates: aml-hub.com/medical-informat… #AMLsm #leusm

Save the Date! @calliecoombsmd @JohnPLeonardMD @Ramikomrokji @farrukhawan @NicholasShortMD @szusmani @DrKrinaPatel @corinneShahmehdi @jmaakaron @CLachowiez Register at louisville.edu/medicine/cme/… @UofLBCC @UofLHealth @UofLMedicine @uoflmedschool @uofl

MRD is highly prognostic in #AML and can inform SCT decisions or enrollment into MRD-directed clinical trials. MRD endpoints may also allow for accelerated drug approval in AML. New review by @NicholasShortMD and Richard Dillon in @AjHematology doi.org/10.1002/ajh.27482 #leusm

Happy to see our trial of DAC, venetoclax and ponatinib for advanced phase CML published in @TheLancetHaem. Response rate was 80%, allowing for bridge to alloSCT. Still a lot more work to be done in this rare disease. We have new TKI combo studies now open and enrolling.

NGS MRD (clonoSEQ) is the most sensitive and specific MRD assay in Ph #ALL. Therapeutic decision-making should be based on NGS rather than PCR for BCR::ABL1 @NicholasShortMD of @MDAndersonNews #Leukemia doi.org/10.1080/17474086.202… #leusm

Our new review on inotuzumab ozogamicin is now online. We cover the clinical development of INO, pivotal studies, and the novel uses of INO in B-ALL, including combination therapies and use in the frontline setting.

Listening to #NicholasShort from ⁦⁦@MDAndersonNews⁩ talking about #inotuzumab in relapsed refractory Acute lymphoblastic leukemia! Delhi